TD Cowen raises Grail stock price target to $180 on FDA outlook

Grail's Galleri cancer-detection test, priced at $949, is not covered by Medicare. FDA advisory panel supported its effectiveness, safety, and risk-benefit profile. Medicare coverage may start in 2029, but age restrictions could exclude some beneficiaries. Grail expects FDA decision by early Q1 2027. Promotional pricing and other coverage options may reduce out-of-pocket costs.

GRAIL (GRAL) reported Q3 2026 earnings, highlighting a pricing promotion that lowered ASPs to $660 to prioritize volume growth. The company expects FDA approval for Galleri to differentiate it from competitors and drive market bifurcation. GRAIL plans to engage CMS and commercial payers for reimbursement post-approval. International expansion is underway, with UKCA approval in the UK and IVDR submission in Europe. The sales force was expanded to 120 representatives, meeting Q3 volume goals.

GRAIL (GRAL) reported Q3 2026 revenue of $37.5M, up 4% YoY. Test volumes rose 24% YoY to 56,000. FDA advisory committee voted positively on Galleri, a multi-cancer early detection test, with a final decision expected by early Q1 2027. Clinical studies showed Galleri's ability to detect 140+ cancer types with low false positives. Commercial traction continues with 36% YoY volume growth in the first 9 months of 2026.

GRAIL (GRAL) expects an FDA decision on its product by early Q1 2027, following a favorable advisory committee vote. The company updated its 2026 Galleri revenue growth forecast to 17%-21%. CEO Joshua Ofman highlighted recent journal publications and clinical results.

GRAIL (GRAL) reported Q3 revenue of $37.3M, up 14%, with test volume increasing 24%. Adjusted gross margin fell to 42% from 55% YoY. The company maintained 2026 cash burn guidance of no more than $300M. GRAIL cited clinical study results showing increased cancer detection and reductions in advanced-stage diagnoses. They expect FDA approval to support reimbursement efforts.

Grail Inc (GRAL) reported Q3 revenue of $37.5M, missing estimates by 17%. The company posted a loss of $2.21 per share, with revenue up 4% YoY. Galleri test revenue grew 14% YoY to $37.3M. Stock fell 11.5% in after-hours trading. FDA Advisory Committee voted in favor of Galleri test approval. GRAL anticipates an FDA decision by early Q1 2027. Q3 net loss was $103.6M, up from $89.0M YoY.